ABT

SEC source: 0001179110-17-002952 · edgar.xml · nonDerivative · entry 1

CAPEK JOHN M · CIK 0001328034 · Executive Vice President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 288,797

F1 · shares: These shares represent performance vested restricted stock awards under the Abbott Laboratories 2009 Incentive Stock Program. The awards have a 5-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes.

SEC source: 0001179110-17-002953 · edgar.xml · derivative · entry 14

BIRD ROGER · CIK 0001635313 · Senior Vice President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 92,032

Underlying: Common shares · 92,032 shares

Expires 2027-02-16

F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 30,678 on 02/17/2018, 30,677 on 02/17/2019, and 30,677 on 02/17/2020.

SEC source: 0001179110-17-002953 · edgar.xml · nonDerivative · entry 1

BIRD ROGER · CIK 0001635313 · Senior Vice President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 63,910

F1 · shares: These shares represent performance vested restricted stock awards under the Abbott Laboratories 2009 Incentive Stock Program. The awards have a 5-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes.

SEC source: 0001179110-17-002963 · edgar.xml · derivative · entry 5

Funck Robert E · CIK 0001565892 · Vice President, Controller

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 48,831

Underlying: Common shares · 48,831 shares

Expires 2027-02-16

F4 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 16,277 on 2/17/2018, 16,277 on 2/17/2019, and 16,277 on 2/17/2020.

SEC source: 0001179110-17-002963 · edgar.xml · nonDerivative · entry 1

Funck Robert E · CIK 0001565892 · Vice President, Controller

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 92,079

F1 · shares: These shares represent performance vested restricted stock awards under the Abbott Laboratories 2009 Incentive Stock Program. The awards have a 5-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes.

SEC source: 0001179110-17-002965 · edgar.xml · derivative · entry 3

YOOR BRIAN B · CIK 0001643528 · Executive Vice President & CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 136,682

Underlying: Common shares · 136,682 shares

Expires 2027-02-16

F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 45,561 on 2/17/2018, 45,560 on 2/17/2019, and 45,561 on 2/17/2020.

SEC source: 0001179110-17-002965 · edgar.xml · nonDerivative · entry 1

YOOR BRIAN B · CIK 0001643528 · Executive Vice President & CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 69,380

F1 · shares: These shares represent performance vested restricted stock awards under the Abbott Laboratories 2009 Incentive Stock Program. The awards have a 5-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes.

SEC source: 0001179110-17-002964 · edgar.xml · derivative · entry 3

LANE ANDREW H · CIK 0001643735 · Senior Vice President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 112,484

Underlying: Common shares · 112,484 shares

Expires 2027-02-16

F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 37,495 on 02/17/2018, 37,494 on 02/17/2019, and 37,495 on 02/17/2020.

SEC source: 0001179110-17-002966 · edgar.xml · derivative · entry 5

WHITE MILES D · CIK 0001239129 · Director · Chairman and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 638,629

Underlying: Common shares · 638,629 shares

Expires 2027-02-16

F4 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 212,877 on 02/17/2018, 212,876 on 02/17/2019, and 212,876 on 02/17/2020.

SEC source: 0001179110-17-002966 · edgar.xml · nonDerivative · entry 1

WHITE MILES D · CIK 0001239129 · Director · Chairman and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,202,269

F1 · shares: These shares represent performance vested restricted stock awards under the Abbott Laboratories 2009 Incentive Stock Program. The awards have a 5-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes.

SEC source: 0001179110-17-002967 · edgar.xml · derivative · entry 2

ALLEN HUBERT L · CIK 0001565916 · Executive Vice President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 167,056

Underlying: Common shares · 167,056 shares

Expires 2027-02-16

F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 55,686 on 02/17/2018, 55,685 on 02/17/2019, and 55,685 on 02/17/2020.

SEC source: 0001179110-17-002967 · edgar.xml · nonDerivative · entry 1

ALLEN HUBERT L · CIK 0001565916 · Executive Vice President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 112,612

F1 · shares: These shares represent performance vested restricted stock awards under the Abbott Laboratories 2009 Incentive Stock Program. The awards have a 5-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes.

SEC source: 0001179110-17-002968 · edgar.xml · derivative · entry 2

Salvadori Daniel Gesua Sive · CIK 0001620564 · Senior Vice President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 138,049

Underlying: Common shares · 138,049 shares

Expires 2027-02-16

F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 46,017 on 2/17/2018, 46,016 on 2/17/2019, and 46,016 on 2/17/2020.

SEC source: 0001179110-17-002968 · edgar.xml · nonDerivative · entry 1

Salvadori Daniel Gesua Sive · CIK 0001620564 · Senior Vice President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 78,937

F1 · shares: These shares represent performance vested restricted stock awards under the Abbott Laboratories 2009 Incentive Stock Program. The awards have a 5-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes.

SEC source: 0001179110-17-002972 · edgar.xml · derivative · entry 2

Blaser Brian J · CIK 0001492289 · Executive Vice President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 182,242

Underlying: Common shares · 182,242 shares

Expires 2027-02-16

F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 60,748 on 2/17/2018, 60,747 on 2/17/2019, and 60,747 on 2/17/2020.

SEC source: 0001179110-17-002972 · edgar.xml · nonDerivative · entry 1

Blaser Brian J · CIK 0001492289 · Executive Vice President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 171,413

F1 · shares: These shares represent performance vested restricted stock awards under the Abbott Laboratories 2009 Incentive Stock Program. The awards have a 5-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes.

SEC source: 0001179110-17-002973 · edgar.xml · derivative · entry 1

Warmuth Michael J · CIK 0001452290 · Executive Vice President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 205,023

Underlying: Common shares · 205,023 shares

Expires 2027-02-16

F1 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 68,341 on 02/17/2018, 68,341 on 02/17/2019, and 68,341 on 02/17/2020.

SEC source: 0001179110-17-002974 · edgar.xml · derivative · entry 3

MANNING JOSEPH J · CIK 0001695686 · Senior Vice President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 92,032

Underlying: Common shares · 92,032 shares

Expires 2027-02-16

F1 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 30,678 on 2/17/2018, 30,677 on 2/17/2019, and 30,677 on 2/17/2020.

SEC source: 0001179110-17-014957 · edgar.xml · nonDerivative · entry 1

WHITE MILES D · CIK 0001239129 · Director · Chairman and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,207,105

F1 · shares: These shares represent performance vested restricted stock awards under the Abbott Laboratories 2009 Incentive Stock Program. The awards have a 5-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes.

F2 · balance_after: This Form 4/A amends the total amount of Abbott shares beneficially owned to include 4,836 shares held in the Judith S. White Living Trust. The reporting person was appointed trustee of the trust on January 16, 2017 and is the beneficiary of the shares in the trust.

SEC source: 0001179110-17-002457 · edgar.xml · derivative · entry 3

ALLEN HUBERT L · CIK 0001565916 · Executive Vice President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common shares · 3,400 shares

Expires 2017-02-15

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3.

SEC source: 0001179110-17-002457 · edgar.xml · nonDerivative · entry 2

ALLEN HUBERT L · CIK 0001565916 · Executive Vice President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 88,457

SEC source: 0001179110-17-002457 · edgar.xml · nonDerivative · entry 1

ALLEN HUBERT L · CIK 0001565916 · Executive Vice President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 91,857

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001179110-17-001902 · edgar.xml · derivative · entry 3

MANNING JOSEPH J · CIK 0001695686 · Senior Vice President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common shares · 300 shares

Expires 2017-02-15

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3.

SEC source: 0001179110-17-001902 · edgar.xml · nonDerivative · entry 2

MANNING JOSEPH J · CIK 0001695686 · Senior Vice President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,579

SEC source: 0001179110-17-001902 · edgar.xml · nonDerivative · entry 1

MANNING JOSEPH J · CIK 0001695686 · Senior Vice President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,792

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001179110-17-001517 · edgar.xml · derivative · entry 4

Mason Heather L · CIK 0001432601 · Executive Vice President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common shares · 35,700 shares

Expires 2017-02-15

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3.

SEC source: 0001179110-17-001517 · edgar.xml · nonDerivative · entry 2

Mason Heather L · CIK 0001432601 · Executive Vice President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 64,489

SEC source: 0001179110-17-001517 · edgar.xml · nonDerivative · entry 1

Mason Heather L · CIK 0001432601 · Executive Vice President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 100,189

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001179110-17-001518 · edgar.xml · nonDerivative · entry 1

Fussell Stephen R · CIK 0001327700 · Executive Vice President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 167,167

SEC source: 0001104659-17-001247 · a4.xml · derivative · entry 8

ROUSSEAU MICHAEL T · CIK 0001233677 · Pres., Cardiovasc. & Neuromod.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 545,573

Underlying: Common shares without par value · 545,573 shares

Expires 2023-12-07

F6 · price: Pursuant to terms of the Merger Agreement, at the First Effective Time, each unvested St. Jude Medical stock option was canceled and converted into an option to acquire, on substantially the same terms and conditions (except that, subject to the holder's continued employment, the option will fully vest to the extent unvested on the second anniversary of the First Effective Time), a number of Abbott common shares equal to the product (rounded down to the nearest whole share) of (a) the number of St. Jude Medical common shares subject to such option multiplied by (b) the Stock Award Exchange Ratio, at an exercise price per Abbott common share equal to the quotient (rounded up to the nearest whole cent) of (i) the per share exercise price for the St. Jude Medical common shares subject to such assumed option as of immediately prior to the First Effective Time divided by (ii) the Stock Award Exchange Ratio.

F6 · derivative.exercise_date: Pursuant to terms of the Merger Agreement, at the First Effective Time, each unvested St. Jude Medical stock option was canceled and converted into an option to acquire, on substantially the same terms and conditions (except that, subject to the holder's continued employment, the option will fully vest to the extent unvested on the second anniversary of the First Effective Time), a number of Abbott common shares equal to the product (rounded down to the nearest whole share) of (a) the number of St. Jude Medical common shares subject to such option multiplied by (b) the Stock Award Exchange Ratio, at an exercise price per Abbott common share equal to the quotient (rounded up to the nearest whole cent) of (i) the per share exercise price for the St. Jude Medical common shares subject to such assumed option as of immediately prior to the First Effective Time divided by (ii) the Stock Award Exchange Ratio.

F9 · derivative.exercise_date: 181,857 options are scheduled to vest on December 17, 2017, 181,857 options are scheduled to vest on December 17, 2018 and 181,859 options are scheduled to vest on January 4, 2019.

SEC source: 0001104659-17-001247 · a4.xml · derivative · entry 7

ROUSSEAU MICHAEL T · CIK 0001233677 · Pres., Cardiovasc. & Neuromod.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 150,737

Underlying: Common shares without par value · 150,737 shares

Expires 2022-12-08

F6 · price: Pursuant to terms of the Merger Agreement, at the First Effective Time, each unvested St. Jude Medical stock option was canceled and converted into an option to acquire, on substantially the same terms and conditions (except that, subject to the holder's continued employment, the option will fully vest to the extent unvested on the second anniversary of the First Effective Time), a number of Abbott common shares equal to the product (rounded down to the nearest whole share) of (a) the number of St. Jude Medical common shares subject to such option multiplied by (b) the Stock Award Exchange Ratio, at an exercise price per Abbott common share equal to the quotient (rounded up to the nearest whole cent) of (i) the per share exercise price for the St. Jude Medical common shares subject to such assumed option as of immediately prior to the First Effective Time divided by (ii) the Stock Award Exchange Ratio.

F6 · derivative.exercise_date: Pursuant to terms of the Merger Agreement, at the First Effective Time, each unvested St. Jude Medical stock option was canceled and converted into an option to acquire, on substantially the same terms and conditions (except that, subject to the holder's continued employment, the option will fully vest to the extent unvested on the second anniversary of the First Effective Time), a number of Abbott common shares equal to the product (rounded down to the nearest whole share) of (a) the number of St. Jude Medical common shares subject to such option multiplied by (b) the Stock Award Exchange Ratio, at an exercise price per Abbott common share equal to the quotient (rounded up to the nearest whole cent) of (i) the per share exercise price for the St. Jude Medical common shares subject to such assumed option as of immediately prior to the First Effective Time divided by (ii) the Stock Award Exchange Ratio.

F8 · derivative.exercise_date: 75,368 options are scheduled to vest on December 17, 2017 and 75,369 options are scheduled to vest on December 17, 2018.

SEC source: 0001104659-17-001247 · a4.xml · derivative · entry 6

ROUSSEAU MICHAEL T · CIK 0001233677 · Pres., Cardiovasc. & Neuromod.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 77,739

Underlying: Common shares without par value · 77,739 shares

Expires 2021-12-10

F6 · price: Pursuant to terms of the Merger Agreement, at the First Effective Time, each unvested St. Jude Medical stock option was canceled and converted into an option to acquire, on substantially the same terms and conditions (except that, subject to the holder's continued employment, the option will fully vest to the extent unvested on the second anniversary of the First Effective Time), a number of Abbott common shares equal to the product (rounded down to the nearest whole share) of (a) the number of St. Jude Medical common shares subject to such option multiplied by (b) the Stock Award Exchange Ratio, at an exercise price per Abbott common share equal to the quotient (rounded up to the nearest whole cent) of (i) the per share exercise price for the St. Jude Medical common shares subject to such assumed option as of immediately prior to the First Effective Time divided by (ii) the Stock Award Exchange Ratio.

F6 · derivative.exercise_date: Pursuant to terms of the Merger Agreement, at the First Effective Time, each unvested St. Jude Medical stock option was canceled and converted into an option to acquire, on substantially the same terms and conditions (except that, subject to the holder's continued employment, the option will fully vest to the extent unvested on the second anniversary of the First Effective Time), a number of Abbott common shares equal to the product (rounded down to the nearest whole share) of (a) the number of St. Jude Medical common shares subject to such option multiplied by (b) the Stock Award Exchange Ratio, at an exercise price per Abbott common share equal to the quotient (rounded up to the nearest whole cent) of (i) the per share exercise price for the St. Jude Medical common shares subject to such assumed option as of immediately prior to the First Effective Time divided by (ii) the Stock Award Exchange Ratio.

F7 · derivative.exercise_date: These options are scheduled to vest on December 17, 2017.

SEC source: 0001104659-17-001247 · a4.xml · nonDerivative · entry 5

ROUSSEAU MICHAEL T · CIK 0001233677 · Pres., Cardiovasc. & Neuromod.

10b5-1 filing: Not disclosed

Ownership: Indirect · Family Trust

Disclosed balance after: 632,581

F2 · price: Pursuant to terms of the Merger Agreement, at the First Effective Time, each vested St. Jude Medical stock option was deemed exercised pursuant to a cashless exercise and deemed settled by issuance of a number of St. Jude Medical shares equal to the difference (rounded down to the nearest whole share, but with any partial shares otherwise issuable settled in cash) of (a) the number of St. Jude Medical common shares subject to such surrendered St. Jude Medical option as of immediately prior to the First Effective Time minus (b) the number of whole and partial (computed to the nearest four decimal places) St. Jude Medical common shares that, when multiplied by $80.82 (the closing price of a St. Jude Medical common share on January 4, 2017), is equal to the aggregate exercise price of such surrendered St. Jude Medical option. (Continued in footnote 3).

F3 · price: Such St. Jude Medical common shares were then canceled and converted into the right to receive the merger consideration with respect to each St. Jude Medical common share issued in respect of the stock option, less any applicable withholding taxes.

SEC source: 0001104659-17-001247 · a4.xml · nonDerivative · entry 4

ROUSSEAU MICHAEL T · CIK 0001233677 · Pres., Cardiovasc. & Neuromod.

10b5-1 filing: Not disclosed

Ownership: Indirect · Family Trust

Disclosed balance after: 203,486

F1 · price: On January 4, 2017, Abbott Laboratories ("Abbott") acquired St. Jude Medical, Inc. ("St. Jude Medical") pursuant to the Agreement and Plan of Merger by and among Abbott, St. Jude Medical, Vault Merger Sub, Inc. and Vault Merger Sub, LLC dated as of April 27, 2016 (the "Merger Agreement"). Upon the First Effective Time (as defined in the Merger Agreement), each outstanding St. Jude Medical common share (other than certain shares identified in the Merger Agreement) was converted into the right to receive (a) $46.75 in cash, without interest, and (b) 0.8708 common shares of Abbott.

SEC source: 0001104659-17-001247 · a4.xml · nonDerivative · entry 3

ROUSSEAU MICHAEL T · CIK 0001233677 · Pres., Cardiovasc. & Neuromod.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 186,403

F4 · shares: Pursuant to terms of the Merger Agreement, at the First Effective Time, each unvested St. Jude Medical restricted stock unit award was canceled and converted into a restricted stock unit award, with substantially the same terms and conditions as were applicable to such St. Jude Medical award (except that, subject to the holder's continued employment, the award will fully vest to the extent unvested on the second anniversary of the First Effective Time), that is settleable with respect to a number of Abbott common shares equal to the product (rounded to the nearest whole share) of (a) the number of St. Jude Medical shares subject to such award multiplied by (b) 2.0850 (the "Stock Award Exchange Ratio").

F5 · shares: 37,204 restricted stock units are scheduled to vest on December 17, 2017 and will be settled promptly thereafter, 27,876 restricted stock units are scheduled to vest on December 17, 2018 and will be settled promptly thereafter, and 19,314 restricted stock units are scheduled to vest on January 4, 2019 and will be settled December 17, 2019.

SEC source: 0001104659-17-001247 · a4.xml · nonDerivative · entry 2

ROUSSEAU MICHAEL T · CIK 0001233677 · Pres., Cardiovasc. & Neuromod.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 102,010

F2 · price: Pursuant to terms of the Merger Agreement, at the First Effective Time, each vested St. Jude Medical stock option was deemed exercised pursuant to a cashless exercise and deemed settled by issuance of a number of St. Jude Medical shares equal to the difference (rounded down to the nearest whole share, but with any partial shares otherwise issuable settled in cash) of (a) the number of St. Jude Medical common shares subject to such surrendered St. Jude Medical option as of immediately prior to the First Effective Time minus (b) the number of whole and partial (computed to the nearest four decimal places) St. Jude Medical common shares that, when multiplied by $80.82 (the closing price of a St. Jude Medical common share on January 4, 2017), is equal to the aggregate exercise price of such surrendered St. Jude Medical option. (Continued in footnote 3).

F3 · price: Such St. Jude Medical common shares were then canceled and converted into the right to receive the merger consideration with respect to each St. Jude Medical common share issued in respect of the stock option, less any applicable withholding taxes.

SEC source: 0001104659-17-001247 · a4.xml · nonDerivative · entry 1

ROUSSEAU MICHAEL T · CIK 0001233677 · Pres., Cardiovasc. & Neuromod.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,735

F1 · price: On January 4, 2017, Abbott Laboratories ("Abbott") acquired St. Jude Medical, Inc. ("St. Jude Medical") pursuant to the Agreement and Plan of Merger by and among Abbott, St. Jude Medical, Vault Merger Sub, Inc. and Vault Merger Sub, LLC dated as of April 27, 2016 (the "Merger Agreement"). Upon the First Effective Time (as defined in the Merger Agreement), each outstanding St. Jude Medical common share (other than certain shares identified in the Merger Agreement) was converted into the right to receive (a) $46.75 in cash, without interest, and (b) 0.8708 common shares of Abbott.

SEC source: 0001104659-17-001246 · a4.xml · derivative · entry 7

Fain Eric S · CIK 0001402222 · Senior Vice President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 163,268

Underlying: Common shares without par value · 163,268 shares

Expires 2023-12-07

F7 · price: Pursuant to terms of the Merger Agreement, at the First Effective Time, each unvested St. Jude Medical stock option was canceled and converted into an option to acquire, on substantially the same terms and conditions (except that, subject to the holder's continued employment, the option will fully vest to the extent unvested on the second anniversary of the First Effective Time), a number of Abbott common shares equal to the product (rounded down to the nearest whole share) of (a) the number of St. Jude Medical common shares subject to such option multiplied by (b) the Stock Award Exchange Ratio, at an exercise price per Abbott common share equal to the quotient (rounded up to the nearest whole cent) of (i) the per share exercise price for the St. Jude Medical common shares subject to such assumed option as of immediately prior to the First Effective Time divided by (ii) the Stock Award Exchange Ratio.

F7 · derivative.exercise_date: Pursuant to terms of the Merger Agreement, at the First Effective Time, each unvested St. Jude Medical stock option was canceled and converted into an option to acquire, on substantially the same terms and conditions (except that, subject to the holder's continued employment, the option will fully vest to the extent unvested on the second anniversary of the First Effective Time), a number of Abbott common shares equal to the product (rounded down to the nearest whole share) of (a) the number of St. Jude Medical common shares subject to such option multiplied by (b) the Stock Award Exchange Ratio, at an exercise price per Abbott common share equal to the quotient (rounded up to the nearest whole cent) of (i) the per share exercise price for the St. Jude Medical common shares subject to such assumed option as of immediately prior to the First Effective Time divided by (ii) the Stock Award Exchange Ratio.

F10 · derivative.exercise_date: 54,422 options are scheduled to vest on December 17, 2017, 54,422 options are scheduled to vest on December 17, 2018 and 54,424 options are scheduled to vest on January 4, 2019.

SEC source: 0001104659-17-001246 · a4.xml · derivative · entry 6

Fain Eric S · CIK 0001402222 · Senior Vice President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 85,864

Underlying: Common shares without par value · 85,864 shares

Expires 2022-12-08

F7 · price: Pursuant to terms of the Merger Agreement, at the First Effective Time, each unvested St. Jude Medical stock option was canceled and converted into an option to acquire, on substantially the same terms and conditions (except that, subject to the holder's continued employment, the option will fully vest to the extent unvested on the second anniversary of the First Effective Time), a number of Abbott common shares equal to the product (rounded down to the nearest whole share) of (a) the number of St. Jude Medical common shares subject to such option multiplied by (b) the Stock Award Exchange Ratio, at an exercise price per Abbott common share equal to the quotient (rounded up to the nearest whole cent) of (i) the per share exercise price for the St. Jude Medical common shares subject to such assumed option as of immediately prior to the First Effective Time divided by (ii) the Stock Award Exchange Ratio.

F7 · derivative.exercise_date: Pursuant to terms of the Merger Agreement, at the First Effective Time, each unvested St. Jude Medical stock option was canceled and converted into an option to acquire, on substantially the same terms and conditions (except that, subject to the holder's continued employment, the option will fully vest to the extent unvested on the second anniversary of the First Effective Time), a number of Abbott common shares equal to the product (rounded down to the nearest whole share) of (a) the number of St. Jude Medical common shares subject to such option multiplied by (b) the Stock Award Exchange Ratio, at an exercise price per Abbott common share equal to the quotient (rounded up to the nearest whole cent) of (i) the per share exercise price for the St. Jude Medical common shares subject to such assumed option as of immediately prior to the First Effective Time divided by (ii) the Stock Award Exchange Ratio.

F9 · derivative.exercise_date: 42,932 options are scheduled to vest on December 17, 2017 and 42,932 options are scheduled to vest on December 17, 2018.

SEC source: 0001104659-17-001246 · a4.xml · derivative · entry 5

Fain Eric S · CIK 0001402222 · Senior Vice President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 44,387

Underlying: Common shares without par value · 44,387 shares

Expires 2021-12-10

F7 · price: Pursuant to terms of the Merger Agreement, at the First Effective Time, each unvested St. Jude Medical stock option was canceled and converted into an option to acquire, on substantially the same terms and conditions (except that, subject to the holder's continued employment, the option will fully vest to the extent unvested on the second anniversary of the First Effective Time), a number of Abbott common shares equal to the product (rounded down to the nearest whole share) of (a) the number of St. Jude Medical common shares subject to such option multiplied by (b) the Stock Award Exchange Ratio, at an exercise price per Abbott common share equal to the quotient (rounded up to the nearest whole cent) of (i) the per share exercise price for the St. Jude Medical common shares subject to such assumed option as of immediately prior to the First Effective Time divided by (ii) the Stock Award Exchange Ratio.

F7 · derivative.exercise_date: Pursuant to terms of the Merger Agreement, at the First Effective Time, each unvested St. Jude Medical stock option was canceled and converted into an option to acquire, on substantially the same terms and conditions (except that, subject to the holder's continued employment, the option will fully vest to the extent unvested on the second anniversary of the First Effective Time), a number of Abbott common shares equal to the product (rounded down to the nearest whole share) of (a) the number of St. Jude Medical common shares subject to such option multiplied by (b) the Stock Award Exchange Ratio, at an exercise price per Abbott common share equal to the quotient (rounded up to the nearest whole cent) of (i) the per share exercise price for the St. Jude Medical common shares subject to such assumed option as of immediately prior to the First Effective Time divided by (ii) the Stock Award Exchange Ratio.

F8 · derivative.exercise_date: These options are scheduled to vest on December 17, 2017.

SEC source: 0001104659-17-001246 · a4.xml · nonDerivative · entry 4

Fain Eric S · CIK 0001402222 · Senior Vice President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 520,968

F5 · shares: Pursuant to terms of the Merger Agreement, at the First Effective Time, each unvested St. Jude Medical restricted stock unit award was canceled and converted into a restricted stock unit award, with substantially the same terms and conditions as were applicable to such St. Jude Medical award (except that, subject to the holder's continued employment, the award will fully vest to the extent unvested on the second anniversary of the First Effective Time), that is settleable with respect to a number of Abbott common shares equal to the product (rounded to the nearest whole share) of (a) the number of St. Jude Medical shares subject to such award multiplied by (b) 2.0850 (the "Stock Award Exchange Ratio").

F6 · shares: 15,982 restricted stock units are scheduled to vest on December 17, 2017 and will be settled promptly thereafter, 10,657 restricted stock units are scheduled to vest on December 17, 2018 and will be settled promptly thereafter, and 5,779 restricted stock units are scheduled to vest on January 4, 2019 and will be settled December 17, 2019.

SEC source: 0001104659-17-001246 · a4.xml · nonDerivative · entry 3

Fain Eric S · CIK 0001402222 · Senior Vice President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 488,549

F4 · shares: These shares represent restricted stock awards under the Abbott Laboratories 2009 Incentive Stock Program. These awards have a 3-year term and are scheduled to vest on January 4, 2020. The award includes the right to have shares withheld for tax purposes.

SEC source: 0001104659-17-001246 · a4.xml · nonDerivative · entry 2

Fain Eric S · CIK 0001402222 · Senior Vice President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 437,788

F2 · price: Pursuant to terms of the Merger Agreement, at the First Effective Time, each vested St. Jude Medical stock option was deemed exercised pursuant to a cashless exercise and deemed settled by issuance of a number of St. Jude Medical shares equal to the difference (rounded down to the nearest whole share, but with any partial shares otherwise issuable settled in cash) of (a) the number of St. Jude Medical common shares subject to such surrendered St. Jude Medical option as of immediately prior to the First Effective Time minus (b) the number of whole and partial (computed to the nearest four decimal places) St. Jude Medical common shares that, when multiplied by $80.82 (the closing price of a St. Jude Medical common share on January 4, 2017), is equal to the aggregate exercise price of such surrendered St. Jude Medical option. (Continued in footnote 3).

F3 · price: Such St. Jude Medical common shares were then canceled and converted into the right to receive the merger consideration with respect to each St. Jude Medical common share issued in respect of the stock option, less any applicable withholding taxes.

SEC source: 0001104659-17-001246 · a4.xml · nonDerivative · entry 1

Fain Eric S · CIK 0001402222 · Senior Vice President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 115,327

F1 · price: On January 4, 2017, Abbott Laboratories ("Abbott") acquired St. Jude Medical, Inc. ("St. Jude Medical") pursuant to the Agreement and Plan of Merger by and among Abbott, St. Jude Medical, Vault Merger Sub, Inc. and Vault Merger Sub, LLC dated as of April 27, 2016 (the "Merger Agreement"). Upon the First Effective Time (as defined in the Merger Agreement), each outstanding St. Jude Medical common share (other than certain shares identified in the Merger Agreement) was converted into the right to receive (a) $46.75 in cash, without interest, and (b) 0.8708 common shares of Abbott.

SEC source: 0001179110-17-000677 · edgar.xml · nonDerivative · entry 1

Warmuth Michael J · CIK 0001452290 · Executive Vice President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 42,874

F1 · price: On January 4, 2017, Abbott Laboratories ("Abbott") acquired St. Jude Medical, Inc. ("St. Jude Medical") pursuant to the Agreement and Plan of Merger by and among Abbott, St. Jude Medical, Vault Merger Sub, Inc. and Vault Merger Sub, LLC dated as of April 27, 2016 (the "Merger Agreement"). Upon the First Effective Time (as defined in the Merger Agreement), each outstanding St. Jude Medical common share (other than certain shares identified in the Merger Agreement) was converted into the right to receive (a) $46.75 in cash, without interest, and (b) 0.8708 commonshares of Abbott.

SEC source: 0001179110-17-010670 · edgar.xml · nonDerivative · entry 1

Fain Eric S · CIK 0001402222 · Senior Vice President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 116,333

F1 · shares: Due to an administrative error that occurred prior to Abbott's acquisition of St. Jude Medical, Inc., the Form 4 filed on January 6, 2017 underreported the Abbott shares received by the reporting person pursuant to the Agreement and Plan of Merger by and among Abbott, St. Jude Medical, Inc., Vault Merger Sub, Inc., and Vault Merger Sub, LLC, by 413 shares.

F2 · price: On January 4, 2017, Abbott Laboratories ("Abbott") acquired St. Jude Medical, Inc. ("St. Jude Medical") pursuant to the Agreement and Plan of Merger by and among Abbott, St. Jude Medical, Vault Merger Sub, Inc. and Vault Merger Sub, LLC dated as of April 27, 2016 (the "Merger Agreement"). Upon the First Effective Time (as defined in the Merger Agreement), each outstanding St. Jude Medical common share (other than certain shares identified in the Merger Agreement) was converted into the right to receive (a) $46.75 in cash, without interest, and (b) 0.8708 common shares of Abbott.

SEC source: 0001179110-17-000265 · edgar.xml · derivative · entry 1

Alpern Robert J · CIK 0001448074 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,908

Underlying: Common shares · 205 shares

Expires not disclosed

F1 · derivative.exercise_price: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares.

F1 · derivative.exercise_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares.

F1 · derivative.expiration_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares.

F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.

SEC source: 0001179110-17-000266 · edgar.xml · derivative · entry 1

OSBORN WILLIAM A · CIK 0001171797 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 26,963

Underlying: Common shares · 1,015 shares

Expires not disclosed

F1 · derivative.exercise_price: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares.

F1 · derivative.exercise_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares.

F1 · derivative.expiration_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares.

F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.

SEC source: 0001179110-17-000267 · edgar.xml · derivative · entry 1

TILTON GLENN F · CIK 0001194624 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 28,351

Underlying: Common shares · 859 shares

Expires not disclosed

F1 · derivative.exercise_price: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares.

F1 · derivative.exercise_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares.

F1 · derivative.expiration_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares.

F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.

SEC source: 0001179110-17-000268 · edgar.xml · derivative · entry 1

LIDDY EDWARD M · CIK 0001188983 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,113

Underlying: Common shares · 859 shares

Expires not disclosed

F1 · derivative.exercise_price: Director fees credited to a stock equivalent unit account and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares.

F1 · derivative.exercise_date: Director fees credited to a stock equivalent unit account and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares.

F1 · derivative.expiration_date: Director fees credited to a stock equivalent unit account and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares.

F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.